期刊文献+

干扰素λ对人肺腺癌细胞A549的增殖抑制作用及其机制研究 被引量:1

Effects and mechanism of IFNλ on human lung adenocarcinoma A549 cells
下载PDF
导出
摘要 目的:探讨干扰素拉姆达(IFNλ)对人肺腺癌细胞A549的增殖抑制作用及其机制,为治疗肺癌提供理论依据。方法:本文以含有IL-10R1-IFNλR1(10R1-λR1)复合受体的质粒转染人肺腺癌细胞A549。以IL-10刺激转染细胞诱导IFNλ信号表达,在不同时间点进行细胞计数,用流式细胞术分析TUNEL染色、An-nexinV和PI细胞周期染色,以及活化STAT1的总量。结果:IFNλ对A549细胞增殖的抑制作用优于IFNα和IFNγ。表达10R1-λR1复合受体的A549细胞在IL-10刺激下IFNλ表达增加,TUNEL和AnnexinV染色阳性,PI染色显示细胞周期阻滞在G0/G1期。活化STAT1的表达总量增加,维持活性时间延长。结论:IFNλ信号可诱导人肺腺癌细胞凋亡,可能是通过激活STAT1蛋白实现的。 Objective:To investigate whether IFNλ could induce apoptosis in human lung cells, and provide theo- retic support for the anti - cancer and anti - viral applications of IFNλ. Methods : Being great cell death after IFNλR1 overexpression, a chimeric receptor IL- 10R1 -IFNλR1 (10R1 -kR1 ) was used to transfect A549 lung cancer cells. Transfected cells were stimulated with IL - 10 to induce IFNλ signaling, and cell numbers were counted at dif- ferent time points. TUNEL assay, Annexin V staining and PI cell - cycle staining were conducted by using flow cy- tometry. The activated STAT1 protein levels were determined by flow cytometry. Results: IFNλ signaling inhibited A549 cell proliferation, better than IFNα or IFNλ. A549 cells expressing 10R1 - λR1 IL - 10 stimulation. TUNEL assay and Annexin V staining were both positive upon activated IFNλ signaling. The cell cycle was blocked at G0/G1 phase. The intensity and duration of activated STAT1 were stronger in A549 cells expressing 10R1 - λR1 stimulated by IL- 10 than in intact A549 cells stimulated by IFNλ. Conclusion: IFNλ signaling could induce apoptosis in lung carcinoma cell A549, which may via intensified and prolonged STAT1 activation.
出处 《现代肿瘤医学》 CAS 2012年第7期1337-1340,共4页 Journal of Modern Oncology
基金 北京市属高等学校人才强教计划资助项目(PHR201007112)
关键词 干扰素拉姆达 凋亡 肺腺癌 复合受体 interferon lambda apoptosis lung adenocarcinoma chimeric receptor
  • 相关文献

参考文献14

  • 1Schindler C, Plumlee C. Inteferons pen the JAK - STAT pathway [J]. Semin Cell Dev Biol, 2008, 19:311 -318.
  • 2Sheppard P, Kindsvogel W, Xu W, et al. IL - 28, IL - 29 and their class II cytokine receptor IL-28R[J]. Nat Immunol, 2003, 4:63-68.
  • 3Kotenko SV, Gallagher G, Baurin VV, et al. IFN - lambdas mediate antiviral protection through a distinct class II cytokine receptor complex[ J]. Nat Immunol, 2003,4 : 69 - 77.
  • 4Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting [ J ]. Nat Immunol, 2005, 6 : 722 -729.
  • 5Negro F. Adverse effects of drugs in the treatment of viral hepatitis [ J]. Best Pract Res Clin Gastroenterol, 2010, 24:183 -192.
  • 6Kelly C, Kleneiman P, Barnes E. Interferon lambdas: the next cytokine storm[ J]. Gut, 2011,60 : 1284 - 1293.
  • 7Chawla - Sarkar M, Lindner D J, Liu YF, et al. Apoptosis and interferons : role of interferon - stimulated genes as mediators of apoptosis[ J ]. Apoptosis, 2003, 8:237 - 249.
  • 8Clemens MJ. Interferons and apoptosis[J]. J Interferon Cytokine Res, 2003, 23 : 277 - 292.
  • 9Kotenko SV, Izotova LS, Pollack BP, et al. Interaction between the components of the interferon gamma receptor complex [ J ]. J Biol Chem, 1995, 270 : 20915 - 20921.
  • 10Dumoutier L, Tounsi A, Michiels T, et al. Role of the interleu- kin (IL) -28 receptor tyrosine residues for antiviral and antipro- liferative activity of IL - 29/interferon - lambda 1 : similarities with type I interferon signaling [ J]. J Biol Chem, 2004, 279 : 32269 - 32274.

同被引文献36

  • 1Sheppard P,Kindsvogel W,Xu W,et al. IL-28,IL-29 and theirclass II cytokine receptor IL - 28R [ J] . Nature Immunol,2003,4(1):63 -68.
  • 2Kotenko SV,Gallagher G,Baurin VV,et al. IFN - Xs mediate anti-viral protection through a distinct class II cytokine receptor complex[J] . Nature Immunol ,2003 ,4(1) ;69 -77.
  • 3Onoguchi K,Yoneyama M,Takemura A,et al. Viral infections acti-vate types I and HI interferon genes through a common mechanism[J]. J Biol Chem,2007,282 (10 ) :7576 - 7581.
  • 4Li M,Liu X,Zhou Y,et al. Interferon - Xs;the modulators of anti-virus ,antitumor, and immune responses [ J ] - J Leukocyte Biol,2009,86(1) :23 -32.
  • 5Coccia EM,Severa M,Giacomini E,et al. Viral infection and Toll -like receptor agonists induce a differential expression of type I andlambda interferons in human plasmacytoid and monocytederiveddendritic cells[ J]. Eur J Immunol ,2004,34(3) :796- 805.
  • 6Muir AJ,Shiffman ML,Zaman A,et al. Phase lb study of pegylatedinterferon lambda 1 with or without ribavirin in patients with chron-ic genotype 1 hepatitis C vims infection [ J ]. Hepatology, 2010,52(3);822 -832.
  • 7Dumoutier L,Lejeune D ,Hor S,et al. Cloning of a new type II cy-tokine receptor activating signal transducer and activator of tran-scription (STAT) 1, STAT2 and STAT3 [ J]. Biochem J,2003 ,370(2);391 -396.
  • 8Witte K, Witte E,Sabat R,et al. IL - 28A, IL - 28B ,and IL-29;Promising cytokines with type I interferon - like properties [ J] ‘ Cy-tokine Growth Factor Rev,2010,21 (4) :237 - 251.
  • 9Dumoutier L,Tounsi A, Michiels T, et al. Role of the interleukin(IL) - 28 receptor tyrosine residues for antiviral and antiprolifera-tive activity of IL - 29/inteiferon - XI: similarities with type I in-terferon signaling [ J] . J Biol Chem,2004, 279 ( 31 ) : 32269 -32274.
  • 10Meager A . Visvalingam K,Dilger P,et al. Biological activity of in-terleukins -8 And - 9 : Comparison with type I interferons [ J ] .Cytokine,2005,31(2) :109-118.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部